SCHEMBL13614227

SCHEMBL13614227

Cc1ccc(CC[C@@](C)(N)CO)cc1

nearest known ligand 0.47

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 1/20 0.47
CYP2A6 P11509 1/20 0.47
TAAR1 Q96RJ0 1/20 0.47
S1PR1 P21453 7/20 0.45
TNNC1 P63316 5/20 0.45
S1PR3 Q99500 5/20 0.45
S1PR4 O95977 2/20 0.45
S1PR5 Q9H228 2/20 0.45
SGPL1 O95470 1/20 0.45
GPR183 P32249 1/20 0.45
CERS2 Q96G23 1/20 0.45
SPHK2 Q9NRA0 3/20 0.41
IDO1 P14902 1/20 0.40
NPC1 O15118 1/20 0.40
RAB9A P51151 1/20 0.40
SMN1; SMN2 Q16637 1/20 0.40
SPHK1 Q9NYA1 1/20 0.39
IGF1R P08069 1/20 0.38
ALOX15 P16050 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13041615 0.83 CYP2A6 (0.41) CYP1A2CYP2A6S1PR1TNNC1S1PR3
SCHEMBL9183600 0.82 TAAR1 (0.47) CYP2A6TAAR1S1PR1TNNC1S1PR3
SCHEMBL904106 0.82 S1PR1 (0.64) CYP1A2CYP2A6TAAR1S1PR1TNNC1
SCHEMBL5428396 0.82 TAAR1 (0.47) CYP2A6TAAR1S1PR1TNNC1S1PR3
SCHEMBL9427612 0.79 CYP1A2 (0.54) CYP1A2CYP2A6TAAR1S1PR1TNNC1
SCHEMBL7622550 0.79 S1PR1 (0.73) S1PR1TNNC1S1PR3S1PR4S1PR5
SCHEMBL5989142 0.79 S1PR1 (0.73) S1PR1TNNC1S1PR3S1PR4S1PR5
SCHEMBL7615757 0.79 S1PR1 (0.73) S1PR1TNNC1S1PR3S1PR4S1PR5
SCHEMBL12696488 0.79 S1PR1 (0.73) S1PR1TNNC1S1PR3S1PR4S1PR5
SCHEMBL565320 0.78 S1PR1 (0.60) S1PR1TNNC1S1PR3S1PR4S1PR5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7612238-B2 Such as (R)-2-amino-2-methyl-4-[4-(4,4,5,5,5-pentafluoro-pentyloxy)-phenyl]-butan-1-ol hydrochloride for treatment of disorders or diseases mediated by lymphocytes, and for treating acute or chronic transplant rejection or T-cell-mediated inflammatory or autoimmune diseases NOVARTIS AG (CH) 2009-11-03 US disclosed